Logo
x

Search

Subscribe Now

Jazz pharmaceuticals

Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC)

Jazz Pharmaceuticals’ Ziihera (Zanidatamab-hrii) Secures the US FDA’s Accelerated Approval to Treat HER2-Positive (IHC 3+) Biliary...

  • November 21, 2024
Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program

Jazz Pharmaceuticals Reports Acquisition of Redx Pharma’s KRAS Inhibitor Program

  • February 8, 2024
Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in Solid Tumors

Jazz Pharmaceuticals Enters into a 5-Year Research Collaboration Agreement with MD Anderson Cancer Center to Study Zanidatamab in...

  • November 8, 2023
Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

Top 20 Drugs with US Patent Expiry in 2023 Based on Total Sales Value

  • March 29, 2023
Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England

Jazz Pharmaceuticals’ Epidyolex (cannabidiol) Receives NICE Recommendation for the Reimbursement to Treat Seizures in England

  • February 1, 2023
Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients

Jazz Pharmaceuticals Exercised its Option to Advance Zymeworks' Zanidatamab for Cancer Patients

  • December 22, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.